Symbols / ALEC Stock $2.28 +6.05% Alector, Inc.

Healthcare • Biotechnology • United States • NMS
ALEC (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Arnon Rosenthal Ph.D.
Exch · Country NMS · United States
Market Cap 253.14M
Enterprise Value 66.74M
Income -125.39M
Sales 18.42M
FCF (ttm) -119.11M
Book/sh 0.09
Cash/sh 1.86
Employees 103
Insider 10d —
IPO Feb 07, 2019
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -3.26
PEG —
P/S 13.74
P/B 24.26
P/C —
EV/EBITDA -0.52
EV/Sales 3.62
Quick Ratio 5.04
Current Ratio 5.25
Debt/Eq 332.77
LT Debt/Eq —
EPS (ttm) -1.19
EPS next Y -0.70
EPS Growth —
Revenue Growth -71.50%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-11
Earnings (prior) 2026-05-11
ROA -25.71%
ROE -238.85%
ROIC —
Gross Margin 0.00%
Oper. Margin -23.82%
Profit Margin 0.00%
Shs Outstand 111.03M
Shs Float 87.23M
Insider Own 9.57%
Instit Own 80.96%
Short Float 4.77%
Short Ratio 7.92
Short Interest 5.00M
52W High 3.40
vs 52W High -32.94%
52W Low 1.01
vs 52W Low 125.74%
Beta 0.65
Impl. Vol. 3.41%
Rel Volume 0.39
Avg Volume 687.88K
Volume 265.07K
Target (mean) $3.10
Tgt Median $2.00
Tgt Low $1.00
Tgt High $6.00
# Analysts 5
Recom Hold
Prev Close $2.15
Price $2.28
Change 6.05%
About

Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$3.10
Mean price target
2. Current target
$2.28
Latest analyst target
3. DCF / Fair value
$-19.31
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.28
Low
$1.00
High
$6.00
Mean
$3.10

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-15 up Cantor Fitzgerald Neutral → Overweight —
2026-03-10 up BTIG Neutral → Buy $6
2025-10-22 down TD Cowen Buy → Hold —
2025-10-22 down Cantor Fitzgerald Overweight → Neutral —
2025-10-22 main HC Wainwright & Co. Buy → Buy $5
2025-10-22 down William Blair Outperform → Market Perform —
2025-10-22 down BTIG Buy → Neutral —
2025-09-25 reit BTIG Buy → Buy $5
2025-07-28 up Mizuho Neutral → Outperform $4
2025-05-09 main HC Wainwright & Co. Buy → Buy $10
2025-02-27 reit HC Wainwright & Co. Buy → Buy $7
2024-12-16 down Stifel Buy → Hold $4
2024-11-26 down Morgan Stanley Equal-Weight → Underweight $3
2024-11-26 main BTIG Buy → Buy $5
2024-11-26 reit Cantor Fitzgerald — → Overweight —
2024-11-07 reit HC Wainwright & Co. Buy → Buy $35
2024-09-17 reit Cantor Fitzgerald — → Overweight —
2024-09-09 reit Cantor Fitzgerald — → Overweight —
2024-07-29 reit Cantor Fitzgerald — → Overweight —
2024-06-20 reit Cantor Fitzgerald — → Overweight —
News
RSS: Latest ALEC news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-16 WONG-SARAD GRACE Officer — 1,820 $2.65 $4,823
2026-03-13 ROSENTHAL ARNON Chief Executive Officer — 116,246 $0.00 $0
2026-03-13 BERKLEY NEIL LINDSAY Chief Financial Officer — 54,600 $0.00 $0
2026-03-10 WONG-SARAD GRACE Officer — 1,000 $2.65 $2,650
2026-03-03 WONG-SARAD GRACE Officer — 3,367 $2.08 $7,012
2026-03-02 BERKLEY NEIL LINDSAY Chief Financial Officer — 29,649 $2.12 $62,954
2026-03-02 WONG-SARAD GRACE Officer — 8,071 $2.12 $17,138
2026-03-02 ROSENTHAL ARNON Chief Executive Officer — 81,864 $2.12 $173,822
2026-02-26 WONG-SARAD GRACE Officer — 4,079 $2.50 $10,198
2025-12-05 WONG-SARAD GRACE Officer — 4,753 $1.21 $5,751
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
21.05
-79.07%
100.56
+3.60%
97.06
-27.36%
133.62
Operating Revenue
21.05
-79.07%
100.56
+3.60%
97.06
-27.36%
133.62
Operating Expense
177.05
-27.90%
245.56
-1.31%
248.80
-8.34%
271.45
Research And Development
123.06
-33.81%
185.94
-3.21%
192.12
-8.70%
210.42
Selling General And Administration
53.99
-9.44%
59.62
+5.17%
56.69
-7.12%
61.03
General And Administrative Expense
53.99
-9.44%
59.62
+5.17%
56.69
-7.12%
61.03
Other Gand A
53.99
-9.44%
59.62
+5.17%
56.69
-7.12%
61.03
Total Expenses
177.05
-27.90%
245.56
-1.31%
248.80
-8.34%
271.45
Operating Income
-156.01
-7.59%
-145.00
+4.44%
-151.74
-10.09%
-137.83
Total Operating Income As Reported
-156.01
-7.59%
-145.00
+4.44%
-151.74
-10.09%
-137.83
EBITDA
-146.35
-7.48%
-136.16
+4.71%
-142.89
-10.46%
-129.36
Normalized EBITDA
-146.35
-7.48%
-136.16
+4.71%
-142.89
-10.46%
-129.36
Reconciled Depreciation
9.66
+9.27%
8.84
-0.08%
8.85
+4.44%
8.47
EBIT
-156.01
-7.59%
-145.00
+4.44%
-151.74
-10.09%
-137.83
Net Income
-142.93
-20.06%
-119.05
+8.70%
-130.39
+2.19%
-133.31
Pretax Income
-142.76
-20.05%
-118.92
+5.00%
-125.18
+3.75%
-130.06
Other Income Expense
13.25
-49.20%
26.08
-1.83%
26.56
+241.49%
7.78
Other Non Operating Income Expenses
13.25
-49.20%
26.08
-1.83%
26.56
+241.49%
7.78
Tax Provision
0.17
+31.25%
0.13
-97.54%
5.21
+60.17%
3.25
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-142.93
-20.06%
-119.05
+8.70%
-130.39
+2.19%
-133.31
Net Income From Continuing Operation Net Minority Interest
-142.93
-20.06%
-119.05
+8.70%
-130.39
+2.19%
-133.31
Net Income From Continuing And Discontinued Operation
-142.93
-20.06%
-119.05
+8.70%
-130.39
+2.19%
-133.31
Net Income Continuous Operations
-142.93
-20.06%
-119.05
+8.70%
-130.39
+2.19%
-133.31
Normalized Income
-142.93
-20.06%
-119.05
+8.70%
-130.39
+2.19%
-133.31
Net Income Common Stockholders
-142.93
-20.06%
-119.05
+8.70%
-130.39
+2.19%
-133.31
Diluted EPS
-1.39
-13.01%
-1.23
+21.15%
-1.56
+3.70%
-1.62
Basic EPS
-1.39
-13.01%
-1.23
+21.15%
-1.56
+3.70%
-1.62
Basic Average Shares
103.00
+6.64%
96.59
+15.35%
83.73
+1.54%
82.47
Diluted Average Shares
103.00
+6.64%
96.59
+15.35%
83.73
+1.54%
82.47
Diluted NI Availto Com Stockholders
-142.93
-20.06%
-119.05
+8.70%
-130.39
+2.19%
-133.31
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
293.24
-37.38%
468.30
-24.69%
621.83
-21.05%
787.65
Current Assets
266.45
-37.28%
424.82
-24.92%
565.81
-22.11%
726.43
Cash Cash Equivalents And Short Term Investments
256.02
-38.07%
413.40
-24.68%
548.86
-23.00%
712.85
Cash And Cash Equivalents
65.80
+99.27%
33.02
-55.71%
74.56
-51.69%
154.32
Other Short Term Investments
190.22
-49.99%
380.38
-19.80%
474.31
-15.08%
558.53
Receivables
—
—
0.00
-100.00%
2.59
Prepaid Assets
—
—
—
11.00
Other Current Assets
10.43
-8.69%
11.42
-32.61%
16.95
+54.10%
11.00
Total Non Current Assets
26.79
-38.41%
43.49
-22.37%
56.02
-8.48%
61.21
Net PPE
24.55
-33.81%
37.10
-21.17%
47.06
-11.77%
53.33
Gross PPE
62.05
-11.41%
70.04
-6.75%
75.11
-1.10%
75.94
Accumulated Depreciation
-37.49
-13.82%
-32.94
-17.44%
-28.05
-24.05%
-22.61
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
4.85
+0.00%
4.85
+0.92%
4.80
+1.31%
4.74
Other Properties
32.26
-16.94%
38.84
-11.11%
43.69
-2.86%
44.98
Leases
24.94
-5.37%
26.36
-0.97%
26.62
+1.48%
26.23
Other Non Current Assets
2.23
-65.07%
6.39
-28.71%
8.96
+13.74%
7.88
Total Liabilities Net Minority Interest
262.59
-23.11%
341.50
-29.97%
487.67
-14.92%
573.21
Current Liabilities
69.50
-44.42%
125.06
-29.72%
177.95
+89.69%
93.81
Payables And Accrued Expenses
29.01
+12.45%
25.80
-18.82%
31.77
+28.32%
24.76
Payables
18.98
+133.49%
8.13
-29.18%
11.48
+174.00%
4.19
Accounts Payable
1.69
-23.66%
2.21
-41.32%
3.77
-9.88%
4.19
Other Payable
17.29
+192.34%
5.91
-23.22%
7.70
—
Current Accrued Expenses
10.03
-43.24%
17.67
-12.96%
20.30
-1.34%
20.57
Pensionand Other Post Retirement Benefit Plans Current
12.94
-28.95%
18.21
+19.06%
15.30
+19.90%
12.76
Current Debt And Capital Lease Obligation
9.42
+7.63%
8.75
+3.45%
8.46
+5.00%
8.06
Current Debt
0.37
—
—
—
Other Current Borrowings
0.37
—
—
—
Current Capital Lease Obligation
9.06
+3.45%
8.75
+3.45%
8.46
+5.00%
8.06
Current Deferred Liabilities
6.68
-71.75%
23.66
-71.48%
82.97
+72.04%
48.23
Current Deferred Revenue
6.68
-71.75%
23.66
-71.48%
82.97
+72.04%
48.23
Total Non Current Liabilities Net Minority Interest
193.09
-10.79%
216.44
-30.12%
309.72
-35.39%
479.40
Long Term Debt And Capital Lease Obligation
26.81
-20.60%
33.77
+10.86%
30.46
-13.64%
35.27
Long Term Debt
9.32
-0.70%
9.39
—
—
Long Term Capital Lease Obligation
17.49
-28.26%
24.38
-19.96%
30.46
-13.64%
35.27
Long Term Provisions
—
9.28
-86.16%
67.05
—
Non Current Deferred Liabilities
164.54
-4.43%
172.17
-18.34%
210.84
-52.44%
443.37
Non Current Deferred Revenue
164.54
-4.43%
172.17
-18.34%
210.84
-52.44%
443.37
Other Non Current Liabilities
1.74
+40.76%
1.23
-10.12%
1.37
+80.90%
0.76
Stockholders Equity
30.65
-75.83%
126.80
-5.48%
134.16
-37.44%
214.44
Common Stock Equity
30.65
-75.83%
126.80
-5.48%
134.16
-37.44%
214.44
Capital Stock
0.01
+22.22%
0.01
+12.50%
0.01
+0.00%
0.01
Common Stock
0.01
+22.22%
0.01
+12.50%
0.01
+0.00%
0.01
Share Issued
110.36
+11.38%
99.09
+16.74%
84.88
+2.39%
82.90
Ordinary Shares Number
110.36
+11.38%
99.09
+16.74%
84.88
+2.39%
82.90
Additional Paid In Capital
1,002.53
+4.90%
955.66
+13.22%
844.04
+5.68%
798.70
Retained Earnings
-972.06
-17.24%
-829.13
-16.77%
-710.08
-22.49%
-579.69
Gains Losses Not Affecting Retained Earnings
0.17
-36.40%
0.26
+41.85%
0.18
+104.02%
-4.58
Other Equity Adjustments
0.17
-36.40%
0.26
+41.85%
0.18
+104.02%
-4.58
Total Equity Gross Minority Interest
30.65
-75.83%
126.80
-5.48%
134.16
-37.44%
214.44
Total Capitalization
39.97
-70.65%
136.19
+1.51%
134.16
-37.44%
214.44
Working Capital
196.95
-34.30%
299.76
-22.71%
387.86
-38.69%
632.63
Invested Capital
40.34
-70.38%
136.19
+1.51%
134.16
-37.44%
214.44
Total Debt
36.23
-14.78%
42.52
+9.25%
38.92
-10.18%
43.33
Capital Lease Obligations
26.54
-19.88%
33.13
-14.87%
38.92
-10.18%
43.33
Net Tangible Assets
30.65
-75.83%
126.80
-5.48%
134.16
-37.44%
214.44
Tangible Book Value
30.65
-75.83%
126.80
-5.48%
134.16
-37.44%
214.44
Current Provisions
11.45
-76.46%
48.63
+23.31%
39.44
—
Duefrom Related Parties Current
—
—
0.00
-100.00%
2.59
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-184.03
+19.95%
-229.91
-24.84%
-184.16
-805.91%
-20.33
Cash Flow From Continuing Operating Activities
-184.03
+19.95%
-229.91
-24.84%
-184.16
-805.91%
-20.33
Net Income From Continuing Operations
-142.93
-20.06%
-119.05
+8.70%
-130.39
+2.19%
-133.31
Depreciation Amortization Depletion
9.66
+9.27%
8.84
-0.08%
8.85
+4.44%
8.47
Depreciation
9.66
+9.27%
8.84
-0.08%
8.85
+4.44%
8.47
Depreciation And Amortization
9.66
+9.27%
8.84
-0.08%
8.85
+4.44%
8.47
Other Non Cash Items
0.29
—
—
—
Stock Based Compensation
26.66
-32.45%
39.46
-7.79%
42.80
-7.26%
46.15
Asset Impairment Charge
2.92
+32.52%
2.21
0.00
0.00
Operating Gains Losses
—
—
0.05
—
Gain Loss On Sale Of PPE
—
0.00
-100.00%
0.05
0.00
Change In Working Capital
-74.06
+49.62%
-146.99
-63.05%
-90.15
-251.44%
59.53
Change In Receivables
—
0.00
-100.00%
2.59
-46.15%
4.80
Change In Prepaid Assets
0.99
-82.05%
5.53
+192.89%
-5.95
-51.53%
-3.93
Change In Payables And Accrued Expense
-2.05
+28.96%
-2.89
-129.27%
9.87
+405.92%
-3.23
Change In Accrued Expense
-12.90
-3895.29%
0.34
-86.65%
2.55
+195.89%
-2.65
Change In Payable
10.85
+435.94%
-3.23
-144.09%
7.33
+1380.77%
-0.57
Change In Account Payable
-0.52
+63.64%
-1.44
-282.23%
-0.38
+34.09%
-0.57
Change In Other Working Capital
-21.05
+79.07%
-100.56
-50.58%
-66.78
-200.60%
66.38
Change In Other Current Assets
4.16
+44.68%
2.87
+384.84%
-1.01
-20.84%
-0.83
Change In Other Current Liabilities
-56.11
-8.03%
-51.94
-79.93%
-28.87
-685.90%
-3.67
Investing Cash Flow
196.60
+83.51%
107.13
+5.11%
101.92
+164.09%
-159.01
Cash Flow From Continuing Investing Activities
196.60
+83.51%
107.13
+5.11%
101.92
+164.09%
-159.01
Net PPE Purchase And Sale
-0.04
+96.73%
-1.25
+47.29%
-2.38
+42.17%
-4.12
Purchase Of PPE
-0.04
+96.73%
-1.25
+47.29%
-2.38
+42.17%
-4.12
Capital Expenditure
-0.04
+96.73%
-1.25
+47.29%
-2.38
+42.17%
-4.12
Net Investment Purchase And Sale
196.64
+81.42%
108.39
+3.92%
104.30
+167.33%
-154.90
Purchase Of Investment
-271.88
+41.87%
-467.74
+15.22%
-551.73
+0.93%
-556.90
Sale Of Investment
468.52
-18.68%
576.13
-12.18%
656.03
+63.19%
402.00
Financing Cash Flow
20.21
-75.21%
81.54
+3097.65%
2.55
-43.51%
4.51
Cash Flow From Continuing Financing Activities
20.21
-75.21%
81.54
+3097.65%
2.55
-43.51%
4.51
Net Issuance Payments Of Debt
0.00
-100.00%
9.39
0.00
0.00
Issuance Of Debt
0.00
-100.00%
9.39
0.00
0.00
Long Term Debt Issuance
0.00
-100.00%
9.39
0.00
0.00
Net Long Term Debt Issuance
0.00
-100.00%
9.39
0.00
0.00
Net Common Stock Issuance
19.98
-71.90%
71.11
0.00
0.00
Proceeds From Stock Option Exercised
0.23
-77.76%
1.04
-59.10%
2.55
-43.51%
4.51
Changes In Cash
32.78
+179.50%
-41.23
+48.26%
-79.69
+54.42%
-174.83
Beginning Cash Position
34.87
-54.18%
76.10
-51.15%
155.79
-52.88%
330.62
End Cash Position
67.65
+94.02%
34.87
-54.18%
76.10
-51.15%
155.79
Free Cash Flow
-184.07
+20.37%
-231.16
-23.92%
-186.54
-663.08%
-24.45
Interest Paid Supplemental Data
0.85
0.00
—
—
Amortization Of Securities
-6.58
+54.25%
-14.38
+6.13%
-15.32
-1217.11%
-1.16
Common Stock Issuance
19.98
-71.90%
71.11
0.00
0.00
Issuance Of Capital Stock
19.98
-71.90%
71.11
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category